0001209191-12-003889.txt : 20120117 0001209191-12-003889.hdr.sgml : 20120116 20120117170647 ACCESSION NUMBER: 0001209191-12-003889 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120112 FILED AS OF DATE: 20120117 DATE AS OF CHANGE: 20120117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Williamson Robert F III CENTRAL INDEX KEY: 0001397331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33428 FILM NUMBER: 12530205 MAIL ADDRESS: STREET 1: 140 LASALLE AVENUE CITY: PIEDMONT STATE: CA ZIP: 94610 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pharmasset Inc CENTRAL INDEX KEY: 0001301081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 303-A COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-613-4100 MAIL ADDRESS: STREET 1: 303-A COLLEGE ROAD EAST CITY: PRINCETON STATE: NJ ZIP: 08540 4 1 c26691_4x0.xml MAIN DOCUMENT DESCRIPTION X0304 4 2012-01-12 1 0001301081 Pharmasset Inc VRUS 0001397331 Williamson Robert F III 303-A COLLEGE ROAD EAST PRINCETON NJ 08540 1 0 0 0 Common Stock 2012-01-12 4 U 0 7000 137.00 D 0 D Stock Option (Right to Buy) 1.94 2012-01-12 4 D 0 13333.33 0 D 2016-05-24 Common Stock 13333.33 0 D Stock Option (Right to Buy) 1.94 2012-01-12 4 D 0 16000 0 D 2016-05-24 Common Stock 16000 0 D Stock Option (Right to Buy) 2.01 2012-01-12 4 D 0 13333.33 0 D 2016-11-07 Common Stock 13333.33 0 D Stock Option (Right to Buy) 6.84 2012-01-12 4 D 0 20000 0 D 2017-10-10 Common Stock 20000 0 D Stock Option (Right to Buy) 10.10 2012-01-12 4 D 0 20000 0 D 2018-07-16 Common Stock 20000 0 D Stock Option (Right to Buy) 9.30 2012-01-12 4 D 0 40000 0 D 2018-10-29 Common Stock 40000 0 D Stock Option (Right to Buy) 10.83 2012-01-12 4 D 0 40000 0 D 2019-10-14 Common Stock 40000 0 D Stock Option (Right to Buy) 16.17 2012-01-12 4 D 0 40000 0 D 2020-10-14 Common Stock 40000 0 D Stock Option (Right to Buy) 83.52 2021-10-11 Common Stock 15000 0 D Represents shares of time vesting restricted stock, reflecting the two-for-one stock split of the Issuer's common stock effective August 31, 2011 (the "Split"), which became unrestricted and eligible for tender pursuant to the Agreement and Plan of Merger between the Issuer and Gilead Sciences, Inc. (the "Merger Agreement"). These options, which reflect the Split and which vested as to 25% on the date of the grant (May 24, 2006), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $135.06 per share, representing the difference between the exercise price of the options and $137.00 per share. These options, which reflect the Split and which vested on the date of grant (May 24, 2006), were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $135.06 per share, representing the difference between the exercise price of the options and $137.00 per share. These options, which reflect the Split and which vested as to 25% on the date of grant (November 7, 2006), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $134.99 per share, representing the difference between the exercise price of the options and $137.00 per share. These options, which reflect the Split and which vested as to 25% on the date of grant (October 10, 2007), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $130.16 per share, representing the difference between the exercise price of the options and $137.00 per share. These options, which reflect the Split and which vested as to 25% on the date of grant (July 16, 2008), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $126.90 per share, representing the difference between the exercise price of the options and $137.00 per share. These options, which reflect the Split and which vested as to 25% on the date of grant (October 29, 2008), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $127.70 per share, representing the difference between the exercise price of the options and $137.00 per share. These options, which reflect the Split and which provided for vesting as to 25% on the date of grant (October 14, 2009), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $126.17 per share, representing the difference between the exercise price of the options and $137.00 per share. These options, which reflect the Split and which provided for vesting as to 25% on the date of grant (October 14, 2010), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $120.83 per share, representing the difference between the exercise price of the options and $137.00 per share. These options, which provided for vesting as to 25% on the date of grant (October 11, 2011), as to 25% on the first anniversary thereof, and as to an additional 6.25% quarterly thereafter for the following two years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $53.48 per share, representing the difference between the exercise price of the options and $137.00 per share. /s/ Bryce A. Roberts, Attorney in Fact for Robert F. Williamson III 2012-01-17